Personalized Management of Type 2 Diabetes Using AI-Guided (GenAIS TM) Dietary Supplementation

S.LAB (SOLOWAYS)

Status

Completed

Conditions

Diabetes

Treatments

Other: The AI-guided practice dietary supplements group

Other: The standard practice dietary supplements intervention

Study type

Interventional

Funder types

Other

Identifiers

NCT06469658

SW014

Details and patient eligibility

About

This randomized controlled trial investigates the effectiveness of AI-guided dietary supplement prescriptions compared to standard physician-guided prescriptions in managing Type 2 diabetes (T2D). The study includes 160 participants with T2D, aged 40-75, who will be randomly assigned to either the control group (standard physician-guided prescriptions) or the AI-guided group (prescriptions determined by GenAIS, an AI system by Triangel Scientific). The primary objective is to compare the reduction in HbA1c levels between the two groups over 6 months. Secondary outcomes include changes in fasting glucose, lipid profiles, body weight, BMI, hsCRP levels, and adherence to the dietary supplement regimen. The AI system integrates genetic, metabolic, and clinical data to provide personalized supplement recommendations, aiming to improve glycemic control and overall metabolic health.

Enrollment

160 patients

Sex

All

Ages

40 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Age between 40 and 75 years.
Diagnosed with Type 2 diabetes (HbA1c between 7.0% and 10.0%).
Stable anti-diabetic medication regimen for at least 3 months prior to the study.
Willingness to provide genetic and metabolic data.

Exclusion criteria

Type 1 diabetes or other specific types of diabetes.
Significant renal, hepatic, or cardiovascular diseases.
Use of dietary supplements that affect glucose metabolism within the last 3 months.
Pregnancy or breastfeeding